Pricing Log in Create free account
Friday 6 November 2026 Export BLCO’s income statement to Excel — free account

Bausch + Lomb Corporation

BLCO Healthcare Medical Instruments & Supplies

Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.

Revenue
+7.34%
EPS
+222.4%
Free cash flow
+182.5%
Total debt
+2.93%

Quarter to September 2026, against a year earlier

19.94 0.66 −3.20%
Market cap
$7.1B
P/E
0.0×
Fwd P/E
749×
Dividend yield
—
F-score
3/9
Altman Z
0.87
Beneish M
−2.52
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Bausch + Lomb Corporation (BLCO) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Oct 28, 2026 5.02 Departure or appointment of directors or officers Officer departure
10-Q Sep 30, 2026 P1I2: 13 added · 7 removed · 63 modified
P2I1A: no comparison — the earlier filing's Item cannot be compared
8-K Oct 28, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 11, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K/A Aug 5, 2026 5.02 Departure or appointment of directors or officers
8-K Aug 5, 2026 1.01 Entry into a material definitive agreement; 5.02 Departure or appointment of directors or officers; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026
8-K Jul 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 20, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K Apr 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 13 added · 5 removed · 44 modified
1A: 11 added · 22 removed · 110 modified
7: 53 added · 28 removed · 79 modified
8-K Feb 18, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 2, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits
8-K/A Dec 17, 2025 5.02 Departure or appointment of directors or officers
8-K Dec 17, 2025 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
8-K Dec 12, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 13, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 29, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Jul 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K Apr 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 19, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Jul 31, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 1, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 21, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.